AVO vs SENEA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability. Despite this, Mission Produce has demonstrated strong recent earnings surprises and positive short-term momentum, with a bullish analyst recommendation and significant EPS growth acceleration. However, declining revenue, low profitability margins, and lack of Altman Z-Score data raise concerns about long-term sustainability. The stock trades above its Graham Number of $9.96 at $13.46, suggesting potential overvaluation relative to defensive value standards, though forward P/E of 16.72 implies improving earnings expectations.
SENEA presents a compelling value opportunity, trading significantly below its Graham Number ($174.71) and Intrinsic Value ($382.62). The Piotroski F-Score of 4/9 indicates stable financial health, though not exceptional, while the absence of an Altman Z-Score prevents a definitive bankruptcy risk assessment. The company exhibits strong profitability metrics with an ROE of 13.57% and a very low P/E of 10.81 relative to the sector average. However, the stark divergence between the Current Ratio (4.34) and Quick Ratio (0.70) suggests a high concentration of capital in inventory, which is a key risk in the packaged foods industry.
Compare Another Pair
Related Comparisons
AVO vs SENEA: Head-to-Head Comparison
This page compares Mission Produce, Inc. (AVO) and Seneca Foods Corporation (SENEA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.